News | October 11, 2021
Merck and Ridgeback seek EUA from U.S. FDA for molnupiravir
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
The applicants will only have to get their Good Manufacturing Practices certification validated every five years to retain their licence
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
The agreement will sharpen Cigna's focus on the growth path for its rapidly expanding global health portfolio
The platform will provide a safe and nurturing space for women, and non-binary individuals
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
Subscribe To Our Newsletter & Stay Updated
